New Branched Polymer Excipients and Emulsions for Enhanced Drug Delivery

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:38 publications

Grant number: EP/R024804/1

Grant search

Key facts

  • Disease

  • Funder

    UK Research and Innovation (UKRI)
  • Principle Investigator

  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    University of Liverpool
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable


This translational science research aims to build upon ongoing work across University of Liverpool and Liverpool School of Tropical medicine. The work aims to accelerate preclinical validation of drugs for Covid-19 treatment and/or prevention. To maximise healthcare impact, the work seeks to establish three direct outputs, namely; 1) Selection of candidates based on in vitro anti-SARS-CoV-2 activity, 2) Demonstration of In vivo pharmacokinetics and distribution supporting treatment and prevention applications, and 3) Demonstration of in vivo performance in mice infected with SARS-CoV-2. We expect the research to provide evidence-based candidates for evaluation in human clinical trials. We will also undertake additional evaluations for low-middle income settings, focussing on scalability and affordability in sub-Saharan Africa and preferring orally delivered medications, with little or no laboratory monitoring.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.

Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.

Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters.

Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research.

Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study.

FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.

WHO Living Guidelines on antivirals for COVID-19 are evidence-based.

The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases.

Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial.